Insights That
Move You Forward
Helping you make smarter decisions, avoid costly missteps, and
bring safe, effective products to market with confidence
Trying to Keep Up in May
May’s Trying to Keep Up episodes covered AI diagnostics, RAPID, FDA leadership changes, PCCPs, real-world evidence, cybersecurity, and the evolving future of MedTech regulation—plus the month’s best terrible jokes.
What Happens After Clinical Trial Close-Out: Transitioning to Reimbursement
Clinical trial close-out is no longer the end of the development process. In 2026, sponsors must transition quickly from regulatory evidence generation to reimbursement and market access planning. Learn how clinical strategy, real-world evidence, payer expectations, and post-market planning now shape commercialization success for medical devices and combination products.
The Growing Role of Real-World Evidence in Regulatory Decisions
Real-world evidence (RWE) is reshaping regulatory decisions, supplementing clinical trial data with insights from EHRs, registries, and digital tools. Regulators now rely on RWE to strengthen approvals and post-market surveillance. See how NMCG helps sponsors design data strategies that anticipate this evolving landscape.